Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes.
chronic allograft failure
chronic kidney disease
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
22
01
2022
accepted:
02
06
2022
pubmed:
21
7
2022
medline:
19
1
2023
entrez:
20
7
2022
Statut:
ppublish
Résumé
Sensitive and specific biomarkers are needed to provide better biologic insight into the risk of incident and progressive CKD. However, studies have been limited by sample size and design heterogeneity. In this assessment of the prognostic value of preclinical plasma and urine biomarkers for CKD outcomes, we searched Embase (Ovid), MEDLINE ALL (Ovid), and Scopus up to November 30, 2020, for studies exploring the association between baseline kidney biomarkers and CKD outcomes (incident CKD, CKD progression, or incident ESKD). We used random-effects meta-analysis. After screening 26,456 abstracts and 352 full-text articles, we included 129 studies in the meta-analysis for the most frequently studied plasma biomarkers (TNFR1, FGF23, TNFR2, KIM-1, suPAR, and others) and urine biomarkers (KIM-1, NGAL, and others). For the most frequently studied plasma biomarkers, pooled RRs for CKD outcomes were 2.17 (95% confidence interval [95% CI], 1.91 to 2.47) for TNFR1 (31 studies); 1.21 (95% CI, 1.15 to 1.28) for FGF-23 (30 studies); 2.07 (95% CI, 1.82 to 2.34) for TNFR2 (23 studies); 1.51 (95% CI, 1.38 to 1.66) for KIM-1 (18 studies); and 1.42 (95% CI, 1.30 to 1.55) for suPAR (12 studies). For the most frequently studied urine biomarkers, pooled RRs were 1.10 (95% CI, 1.05 to 1.16) for KIM-1 (19 studies) and 1.12 (95% CI, 1.06 to 1.19) for NGAL (19 studies). Studies of preclinical biomarkers for CKD outcomes have considerable heterogeneity across study cohorts and designs, limiting comparisons of prognostic performance across studies. Plasma TNFR1, FGF23, TNFR2, KIM-1, and suPAR were among the most frequently investigated in the setting of CKD outcomes.
Sections du résumé
BACKGROUND
Sensitive and specific biomarkers are needed to provide better biologic insight into the risk of incident and progressive CKD. However, studies have been limited by sample size and design heterogeneity.
METHODS
In this assessment of the prognostic value of preclinical plasma and urine biomarkers for CKD outcomes, we searched Embase (Ovid), MEDLINE ALL (Ovid), and Scopus up to November 30, 2020, for studies exploring the association between baseline kidney biomarkers and CKD outcomes (incident CKD, CKD progression, or incident ESKD). We used random-effects meta-analysis.
RESULTS
After screening 26,456 abstracts and 352 full-text articles, we included 129 studies in the meta-analysis for the most frequently studied plasma biomarkers (TNFR1, FGF23, TNFR2, KIM-1, suPAR, and others) and urine biomarkers (KIM-1, NGAL, and others). For the most frequently studied plasma biomarkers, pooled RRs for CKD outcomes were 2.17 (95% confidence interval [95% CI], 1.91 to 2.47) for TNFR1 (31 studies); 1.21 (95% CI, 1.15 to 1.28) for FGF-23 (30 studies); 2.07 (95% CI, 1.82 to 2.34) for TNFR2 (23 studies); 1.51 (95% CI, 1.38 to 1.66) for KIM-1 (18 studies); and 1.42 (95% CI, 1.30 to 1.55) for suPAR (12 studies). For the most frequently studied urine biomarkers, pooled RRs were 1.10 (95% CI, 1.05 to 1.16) for KIM-1 (19 studies) and 1.12 (95% CI, 1.06 to 1.19) for NGAL (19 studies).
CONCLUSIONS
Studies of preclinical biomarkers for CKD outcomes have considerable heterogeneity across study cohorts and designs, limiting comparisons of prognostic performance across studies. Plasma TNFR1, FGF23, TNFR2, KIM-1, and suPAR were among the most frequently investigated in the setting of CKD outcomes.
Identifiants
pubmed: 35858701
pii: 00001751-202209000-00010
doi: 10.1681/ASN.2022010098
pmc: PMC9529190
doi:
Substances chimiques
Lipocalin-2
0
Receptors, Tumor Necrosis Factor, Type I
0
Receptors, Tumor Necrosis Factor, Type II
0
Receptors, Urokinase Plasminogen Activator
0
Biomarkers
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1657-1672Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK128538
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK096549
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115562
Pays : United States
Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al.; GBD Chronic Kidney Disease Collaboration: Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 395: 709–733, 2020
USRDS. 2017 USRDS Annual Data Report: Executive Summary . Available at: https://www.usrds.org/media/1652/v1_00_execsummary_17.pdf . Accessed December 2, 2021
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004
Levin A, Stevens PE: Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85: 49–61, 2014. Available at: https://www.sciencedirect.com/science/article/pii/S0085253815538933?via%3Dihub . Accessed December 2, 2021. 10.1038/KI.2013.444
doi: 10.1038/KI.2013.444
Waikar SS, Rebholz CM, Zheng Z, Hurwitz S, Hsu CY, Feldman HI, et al.; Chronic Kidney Disease Biomarkers Consortium Investigators: Biological variability of estimated GFR and albuminuria in CKD. Am J Kidney Dis 72: 538–546, 2018
Zhang WR, Parikh CR: Biomarkers of acute and chronic kidney disease. Annu Rev Physiol 81: 309–333, 2019
Wen Y, Parikh CR. Current concepts and advances in biomarkers of acute kidney injury. Rev Clin Lab Sci 58: 354–368, 2021 10.1080/10408363.2021.1879000
doi: 10.1080/10408363.2021.1879000
Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, et al.: Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23: 516–524, 2012
Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, et al.: Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD trial. Clin J Am Soc Nephrol 11: 1343–1352, 2016
Foster MC, Coresh J, Bonventre JV, Sabbisetti VS, Waikar SS, Mifflin TE, et al.; CKD Biomarkers Consortium: Urinary biomarkers and risk of ESRD in the atherosclerosis risk in communities study. Clin J Am Soc Nephrol 10: 1956–1963, 2015
Yuan CH, Xie D, Waikar SS, Bonventre JV, Zhang X, Sabbisette V, et al.: Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int 91: 196–203, 2017
Coca SG, Nadkarni GN, Huang Y, Moledina DG, Rao V, Zhang J, et al.: Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 28: 2786–2793, 2017
Schrauben SJ, Shou H, Zhang X, Anderson AH, Bonventre JV, Chen J, et al.; CKD Biomarkers Consortium and the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Soc Nephrol 32: 115–126, 2021
Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, et al.: Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23: 507–515, 2012
Panduru NM, Sandholm N, Forsblom C, Saraheimo M, Dahlström EH, Thorn LM, et al.; FinnDiane Study Group: Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: A likely causal link in patients with type 1 diabetes. Diabetes Care 38: 1130–1137, 2015
Bramer W, Bain P: Updating search strategies for systematic reviews using EndNote. J Med Libr Assoc 105: 285–289, 2017
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71, 2021
Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at: https://www.covidence.org/ . Accessed December 13, 2021.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177–188, 1986
Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Training. Available at: https://training.cochrane.org/handbook/current . Accessed December 14, 2020.
Zabetian A, Coca SG: Plasma and urine biomarkers in chronic kidney disease: Closer to clinical application. Curr Opin Nephrol Hypertens 30: 531–537, 2021
Al-Lamki RS, Mayadas TN: TNF receptors: Signaling pathways and contribution to renal dysfunction. Kidney Int 87: 281–296, 2015
Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al.: Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55–63, 2007
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al.: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011
Bonventre JV. Kidney injury molecule-1: A translational journey. Trans Am Clin Climatol Assoc. 125: 293–299, 2014
Smith ER, Holt SG, Hewitson TD: FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction. Int J Biochem Cell Biol 92: 63–78, 2017
Puthumana J, Thiessen-Philbrook H, Xu L, Coca SG, Garg AX, Himmelfarb J, et al.: Biomarkers of inflammation and repair in kidney disease progression. J Clin Invest 131: 139927, 2021
Scherberich JE, Gruber R, Nockher WA, Christensen EI, Schmitt H, Herbst V, et al.: Serum uromodulin-a marker of kidney function and renal parenchymal integrity. Nephrol Dial Transplant 33: 284–295, 2018
Menez S, Moledina DG, Garg AX, Thiessen-Philbrook H, McArthur E, Jia Y, et al.: Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery. Kidney Int 99: 716–724, 2020
Menn-Josephy H, Lee CS, Nolin A, Christov M, Rybin DV, Weinberg JM, et al.: Renal interstitial fibrosis: An imperfect predictor of kidney disease progression in some patient cohorts. Am J Nephrol 44: 289–299, 2016
Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kremers WK, et al.: The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med 152: 561–567, 2010
Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, et al.: Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62: 1154–1166, 2019
Sen T, Li J, Neuen BL, Neal B, Arnott C, Parikh CR, et al.: Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2, and KIM-1 in the CANVAS trial. Diabetologia 64: 2147–2158, 2021
Hu C, Dignam JJ. Biomarker-driven oncology clinical trials: Key design elements, types, features, and practical considerations. JCO Precis Oncol 3: 1–12, 2019 10.1200/PO.19.00086
doi: 10.1200/PO.19.00086
Ibrahim NE, Gaggin HK, Konstam MA, Januzzi JL Jr: Established and emerging roles of biomarkers in heart failure clinical trials. Circ Heart Fail 9: e002528, 2016